UY37477A - Potenciadores de bmp - Google Patents

Potenciadores de bmp

Info

Publication number
UY37477A
UY37477A UY0001037477A UY37477A UY37477A UY 37477 A UY37477 A UY 37477A UY 0001037477 A UY0001037477 A UY 0001037477A UY 37477 A UY37477 A UY 37477A UY 37477 A UY37477 A UY 37477A
Authority
UY
Uruguay
Prior art keywords
potentiators
bmp
formula
methods
compounds
Prior art date
Application number
UY0001037477A
Other languages
English (en)
Spanish (es)
Inventor
LARRAUFIE Marie-Helene
Deborah Rothman
Nik Savage
Shaowen Wang
Jian Ding
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37477A publication Critical patent/UY37477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001037477A 2016-11-10 2017-11-09 Potenciadores de bmp UY37477A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662420535P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
UY37477A true UY37477A (es) 2018-06-29

Family

ID=60569967

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037477A UY37477A (es) 2016-11-10 2017-11-09 Potenciadores de bmp

Country Status (15)

Country Link
US (2) US10259827B2 (enExample)
EP (1) EP3538531A1 (enExample)
JP (1) JP2019534302A (enExample)
KR (1) KR20190075120A (enExample)
CN (1) CN109923118A (enExample)
AR (1) AR110163A1 (enExample)
AU (1) AU2017357719A1 (enExample)
BR (1) BR112019009404A2 (enExample)
CA (1) CA3043575A1 (enExample)
EA (1) EA201991141A1 (enExample)
MX (1) MX2019005504A (enExample)
RU (1) RU2019117548A (enExample)
TW (1) TW201821076A (enExample)
UY (1) UY37477A (enExample)
WO (1) WO2018087677A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119751235A (zh) * 2019-01-23 2025-04-04 约翰霍普金斯大学 非免疫抑制性fk506类似物及其用途
WO2026059989A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Peripheral blockers for central nervous system-selective drug activity
WO2026060005A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Macrocyclic blockers for use in the reduction of peripheral side effects due to everolimus therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346427B1 (en) 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
GR1001225B (el) 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
DE4028664A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028676A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028677A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028675A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028666A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
CA2071332A1 (en) * 1991-06-25 1992-12-26 Laszlo R. Treiber C-21 hydroxylated fk-506 antagonist
GB9202196D0 (en) 1992-02-01 1992-03-18 Fisons Plc Method of treatment
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
GB9218027D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9218597D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US7109317B1 (en) * 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
WO2000058318A1 (en) 1999-03-31 2000-10-05 Abbott Laboratories Phosphate containing macrocyclic immunomodulators
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
EP1282626A2 (en) 2000-05-17 2003-02-12 Kosan Biosciences, Inc. Polyketide derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2006206525A1 (en) * 2005-01-20 2006-07-27 Array Biopharma Nc. Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2012047762A2 (en) 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
WO2015106283A1 (en) 2014-01-13 2015-07-16 Amplyx Pharmaceuticals, Inc. Antifungal compounds

Also Published As

Publication number Publication date
CA3043575A1 (en) 2018-05-17
BR112019009404A2 (pt) 2019-07-30
US20180127436A1 (en) 2018-05-10
AU2017357719A1 (en) 2019-05-16
MX2019005504A (es) 2019-08-12
AR110163A1 (es) 2019-02-27
TW201821076A (zh) 2018-06-16
RU2019117548A (ru) 2020-12-10
JP2019534302A (ja) 2019-11-28
CN109923118A (zh) 2019-06-21
WO2018087677A1 (en) 2018-05-17
US10259827B2 (en) 2019-04-16
US20190194227A1 (en) 2019-06-27
EA201991141A1 (ru) 2019-10-31
KR20190075120A (ko) 2019-06-28
EP3538531A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
MX392031B (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2017002703A (es) Sondas para la proyección de imagen de la proteína huntingtina.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MX2016012058A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
EA201791304A1 (ru) Производные изохинолина для лечения вич
ECSP17054980A (es) Inhibidores selectivos de bace1
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
CL2019001804A1 (es) Activador de nrf2.
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX383202B (es) Sondas para la proyección de imagen de la proteína huntingtina.
MX2017002702A (es) Sondas para la proyección de imagen de la proteína huntingtina.
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
MX2019005504A (es) Potenciadores de bmp.
CO2019012594A2 (es) Proceso para la preparación de enantiómeros de pirlindol y sus sales

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230705